» Articles » PMID: 8551603

Mutational Analysis of Human Papillomavirus Type 16 E6 Demonstrates That P53 Degradation is Necessary for Immortalization of Mammary Epithelial Cells

Overview
Journal J Virol
Date 1996 Feb 1
PMID 8551603
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously demonstrated that normal human mammary epithelial cells (MECs) are efficiently immortalized by human papillomavirus type 16 (HPV16) E6. HPV16 E6 binds to and induces p53 degradation in vitro and induces a marked reduction of p53 protein in MECs. Low-risk HPV6 E6 is defective for p53 binding and degradation in vitro but immortalized MECs at low efficiency. The HPV6 E6-immortalized MECs had markedly reduced levels of p53. To directly investigate whether the ability of HPV16 E6 to stimulate p53 degradation is required for E6-induced immortalization, a series of HPV16 E6 mutants were analyzed for the ability to bind and degrade p53 in vitro, induce a reduction in p53 levels in vivo, and immortalize MECs. We observed that one set of mutants efficiently immortalized MECs, caused a reduction in p53 levels in vivo, and degraded p53 in vitro. Other mutants immortalized MECs with low efficiency and either induced p53 degradation at low levels or were unable to induce p53 degradation in vitro; however, all of the immortal clones displayed low levels of p53. A third class of mutants did not immortalize MECs and failed to induce a reduction in p53 levels in vivo or degrade p53 in vitro. These results demonstrate that a reduction in p53 protein levels due to enhanced degradation is essential for MEC immortalization by HPV16 E6.

Citing Articles

Reciprocal transactivation of Merkel cell polyomavirus and high-risk human papillomavirus promoter activities and increased expression of their oncoproteins.

Rasheed K, Sveinbjornsson B, Moens U Virol J. 2021; 18(1):139.

PMID: 34217322 PMC: 8254899. DOI: 10.1186/s12985-021-01613-0.


Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.

Peng S, Ferrall L, Gaillard S, Wang C, Chi W, Huang C mBio. 2021; 12(1).

PMID: 33468698 PMC: 7845631. DOI: 10.1128/mBio.03224-20.


In silico prediction of structural changes in human papillomavirus type 16 (HPV16) E6 oncoprotein and its variants.

Rodriguez-Ruiz H, Garibay-Cerdenares O, Illades-Aguiar B, Montano S, Jiang X, Leyva-Vazquez M BMC Mol Cell Biol. 2019; 20(1):35.

PMID: 31426742 PMC: 6700771. DOI: 10.1186/s12860-019-0217-0.


Human Papillomavirus 11 Early Protein E6 Activates Autophagy by Repressing AKT/mTOR and Erk/mTOR.

Zhang B, Song Y, Sun S, Han R, Hua C, van der Veen S J Virol. 2019; 93(12).

PMID: 30971468 PMC: 6613752. DOI: 10.1128/JVI.00172-19.


Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV Cancers.

Suksanpaisan L, Xu R, Tesfay M, Bomidi C, Hamm S, Vandergaast R Mol Ther Oncolytics. 2018; 10:1-13.

PMID: 29998190 PMC: 6037044. DOI: 10.1016/j.omto.2018.05.001.


References
1.
Liu X, Band H, Gao Q, Wazer D, Chu Q, Band V . Tumor cell-specific loss of p53 protein in a unique in vitro model of human breast tumor progression. Carcinogenesis. 1994; 15(9):1969-73. DOI: 10.1093/carcin/15.9.1969. View

2.
Scheffner M, Huibregtse J, Howley P . Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci U S A. 1994; 91(19):8797-801. PMC: 44693. DOI: 10.1073/pnas.91.19.8797. View

3.
Wazer D, Liu X, Chu Q, Gao Q, Band V . Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci U S A. 1995; 92(9):3687-91. PMC: 42026. DOI: 10.1073/pnas.92.9.3687. View

4.
Chen J, Reid C, Band V, Androphy E . Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science. 1995; 269(5223):529-31. DOI: 10.1126/science.7624774. View

5.
Androphy E, Hubbert N, Schiller J, Lowy D . Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J. 1987; 6(4):989-92. PMC: 553493. DOI: 10.1002/j.1460-2075.1987.tb04849.x. View